[go: up one dir, main page]

MD4277B1 - Use of extract from Spirulina platensis (Nordst) Getil CNMN-CB-02 cyanobacterium strain biomass for the treatment of patients with sensorineural deafness - Google Patents

Use of extract from Spirulina platensis (Nordst) Getil CNMN-CB-02 cyanobacterium strain biomass for the treatment of patients with sensorineural deafness Download PDF

Info

Publication number
MD4277B1
MD4277B1 MDA20130056A MD20130056A MD4277B1 MD 4277 B1 MD4277 B1 MD 4277B1 MD A20130056 A MDA20130056 A MD A20130056A MD 20130056 A MD20130056 A MD 20130056A MD 4277 B1 MD4277 B1 MD 4277B1
Authority
MD
Moldova
Prior art keywords
patients
treatment
getil
nordst
cnmn
Prior art date
Application number
MDA20130056A
Other languages
Moldavian (mo)
Romanian (ro)
Russian (ru)
Other versions
MD4277C1 (en
Inventor
Sergiu Parii
Valeriu Rudic
Original Assignee
Universitatea De Stat De Medicină Şi Farmacie "Nicolae Testemiţanu" Din Republica Moldova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitatea De Stat De Medicină Şi Farmacie "Nicolae Testemiţanu" Din Republica Moldova filed Critical Universitatea De Stat De Medicină Şi Farmacie "Nicolae Testemiţanu" Din Republica Moldova
Priority to MDA20130056A priority Critical patent/MD4277C1/en
Publication of MD4277B1 publication Critical patent/MD4277B1/en
Publication of MD4277C1 publication Critical patent/MD4277C1/en

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to medicine, in particular to otorhinolaryngology and can be used for the treatment of patients with sensorineural deafness.According to the claimed invention, extract from Spirulina platensis (Nordst) Getil CNMN-CB-02 cyanobacterium strain biomass is used for the treatment of patients with sensorineural deafness, 5 mg, 2 times a day, before meals, for 20 days.
MDA20130056A 2013-05-24 2013-05-24 Use of extract from Spirulina platensis (Nordst) Getil CNMN-CB-02 cyanobacterium strain biomass for the treatment of patients with sensorineural deafness MD4277C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20130056A MD4277C1 (en) 2013-05-24 2013-05-24 Use of extract from Spirulina platensis (Nordst) Getil CNMN-CB-02 cyanobacterium strain biomass for the treatment of patients with sensorineural deafness

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20130056A MD4277C1 (en) 2013-05-24 2013-05-24 Use of extract from Spirulina platensis (Nordst) Getil CNMN-CB-02 cyanobacterium strain biomass for the treatment of patients with sensorineural deafness

Publications (2)

Publication Number Publication Date
MD4277B1 true MD4277B1 (en) 2014-03-31
MD4277C1 MD4277C1 (en) 2014-10-31

Family

ID=50685391

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20130056A MD4277C1 (en) 2013-05-24 2013-05-24 Use of extract from Spirulina platensis (Nordst) Getil CNMN-CB-02 cyanobacterium strain biomass for the treatment of patients with sensorineural deafness

Country Status (1)

Country Link
MD (1) MD4277C1 (en)

Also Published As

Publication number Publication date
MD4277C1 (en) 2014-10-31

Similar Documents

Publication Publication Date Title
MX2019009132A (en) Synergistic bacterial compositions and methods of production and use thereof.
BR112013016929A2 (en) human milk oligosaccharides to promote the growth of beneficial bacteria
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
CO2017004932A2 (en) Methods for selecting and donor t cell line for adoptive cell therapy
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
GB2540110A (en) Corneal inlay delivery devices and methods
MX2016016388A (en) Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds.
MX2018006226A (en) 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential.
EA201390417A1 (en) ANTI-DIABETIC SOLID PHARMACEUTICAL COMPOSITIONS
MX2020006075A (en) Bendamustine pharmaceutical compositions.
MD4277B1 (en) Use of extract from Spirulina platensis (Nordst) Getil CNMN-CB-02 cyanobacterium strain biomass for the treatment of patients with sensorineural deafness
UA99921U (en) Method of controlled sedation in patients with alcohol withdrawal condition in the intensive care
MD520Y (en) Method for postoperative treatment of patients with nephrolithiasis
王建平 Treatment of hyperlipoidemia by Xiaozhi capsule: a clinical efficacy research
UA84197U (en) Method for medical rehabilitation of patients with irritated bowel syndrome combined with neurocirculatory dystonia
UA58749U (en) method for treatment of hepatic steatosis in patients with tuberculosis
MD4110B1 (en) Antiherpetic preparation
UA56353U (en) method for restoration of tear-nasal canal in children with administration of drug
UA56675U (en) Method for local treatment generalized periodontitis using using singlent-oxygen therapy
UA64817U (en) method for treatment of patients with syndrome of increased fatigue using apipreparations
UA64822U (en) method for medical rehabilitation of patients with non-alcoholic steatohepatitis
UA71871U (en) Method for diagnostics of effectiveness of antibiotic therapy in patients with lime-boreliosis
UA59272U (en) method for treating of relapsing forms of allergic patients with the presence of secondary immunodeficiency states
UA67522U (en) Method for enhancement of museum strain aurococcus atcc 25923 sensitivity to cefatoxim

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees